IN2012DN03130A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03130A
IN2012DN03130A IN3130DEN2012A IN2012DN03130A IN 2012DN03130 A IN2012DN03130 A IN 2012DN03130A IN 3130DEN2012 A IN3130DEN2012 A IN 3130DEN2012A IN 2012DN03130 A IN2012DN03130 A IN 2012DN03130A
Authority
IN
India
Prior art keywords
propofol
compositions
aerosols
buccal
capsules
Prior art date
Application number
Other languages
English (en)
Inventor
Bastian Theisinger
Sonja Theisinger
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of IN2012DN03130A publication Critical patent/IN2012DN03130A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C19/00Acyclic saturated compounds containing halogen atoms
    • C07C19/08Acyclic saturated compounds containing halogen atoms containing fluorine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN3130DEN2012 2009-11-23 2010-11-22 IN2012DN03130A (th)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09014548A EP2332525A1 (en) 2009-11-23 2009-11-23 Pharmaceutical composition comprising propofol
PCT/EP2010/067938 WO2011061332A1 (en) 2009-11-23 2010-11-22 Pharmaceutical composition comprising propofol

Publications (1)

Publication Number Publication Date
IN2012DN03130A true IN2012DN03130A (th) 2015-09-18

Family

ID=41694756

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3130DEN2012 IN2012DN03130A (th) 2009-11-23 2010-11-22

Country Status (12)

Country Link
US (1) US8796340B2 (th)
EP (2) EP2332525A1 (th)
JP (1) JP5707009B2 (th)
KR (1) KR20120104262A (th)
CN (1) CN102753159B (th)
AU (1) AU2010320823B2 (th)
BR (1) BR112012012108A2 (th)
CA (1) CA2776855C (th)
ES (1) ES2450423T3 (th)
IN (1) IN2012DN03130A (th)
MX (1) MX2012005881A (th)
WO (1) WO2011061332A1 (th)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10045996B2 (en) 2010-03-17 2018-08-14 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DK2714008T3 (en) 2011-05-25 2017-03-13 Novaliq Gmbh PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
GB201116271D0 (en) 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
ES2625538T3 (es) 2012-01-23 2017-07-19 Novaliq Gmbh Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
CN104619314B (zh) 2012-09-12 2017-09-22 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
BR112015005008B1 (pt) 2012-09-12 2022-04-19 Novaliq Gmbh Composições de alcano semifluorado
EP2708228B1 (en) * 2012-09-12 2018-05-16 Novaliq GmbH Eye wash compositions
CN114028560A (zh) 2013-07-23 2022-02-11 诺瓦利克有限责任公司 稳定的抗体组合物
EP2944324A1 (de) * 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
WO2016061538A1 (en) 2014-10-16 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Novel methods, compounds, and compositions for anesthesia
CN113662929A (zh) 2015-09-30 2021-11-19 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
KR20190057338A (ko) 2016-09-23 2019-05-28 노바리크 게엠베하 시클로스포린을 포함하는 안과 조성물
ES2819005T3 (es) 2016-12-23 2021-04-14 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad del ojo seco
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
AU2019228119A1 (en) 2018-03-02 2020-09-10 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
IL276888B2 (en) 2018-03-28 2024-12-01 Novaliq Gmbh Pharmaceutical composition comprising timolol
EP3784246A1 (en) 2018-04-27 2021-03-03 Novaliq GmbH Ophthalmic compositions comprising tafluprost for the treatment of glaucoma
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
EP3923907B1 (en) 2019-02-13 2024-09-25 Novaliq GmbH Compositions and methods for the treatment of ocular neovascularization
AU2020340561B2 (en) 2019-09-06 2026-01-22 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
EP3912622A1 (en) 2020-05-19 2021-11-24 tesa Labtec GmbH Oral film for safe administration of api

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
AU3898700A (en) * 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
GB0124071D0 (en) * 2001-10-08 2001-11-28 Kbig Ltd Improvement in the administration of high boiling point aneasthetics
US20050214379A1 (en) * 2004-01-02 2005-09-29 Sandro Mecozzi Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
DE102004030044A1 (de) 2004-06-22 2006-01-12 Birken Gmbh Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels
US9000048B2 (en) * 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
EP2110126B9 (de) * 2008-04-18 2012-09-19 Novaliq GmbH Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich

Also Published As

Publication number Publication date
EP2503999A1 (en) 2012-10-03
MX2012005881A (es) 2012-06-19
EP2503999B1 (en) 2013-12-25
CN102753159B (zh) 2014-03-12
KR20120104262A (ko) 2012-09-20
BR112012012108A2 (pt) 2016-04-05
AU2010320823A1 (en) 2012-07-12
CA2776855C (en) 2017-10-24
CA2776855A1 (en) 2011-05-26
US8796340B2 (en) 2014-08-05
JP5707009B2 (ja) 2015-04-22
WO2011061332A1 (en) 2011-05-26
US20120238639A1 (en) 2012-09-20
CN102753159A (zh) 2012-10-24
JP2013511496A (ja) 2013-04-04
EP2332525A1 (en) 2011-06-15
AU2010320823B2 (en) 2014-06-26
ES2450423T3 (es) 2014-03-24

Similar Documents

Publication Publication Date Title
MX2013001677A (es) Formulaciones estables de linaclotida.
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
WO2011041729A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011041461A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
BR112012012081A2 (pt) método para o processamento de um arquivo de imagens médicas kobitidas em um procedimento de imagem guiada por protocolo ,equipamento para o processamento de um arquivo de imagens médicas obtidas por um procedimento de imagem guiada por protocolo e elemamto de programa de computador contendo conjuntos de instruções
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
WO2010021607A3 (en) Pharmaceutical formulation
WO2011157722A3 (en) Solid ivabradine-containing composition
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
WO2010049449A3 (en) Novel salts of sunitinib
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
MX2010004899A (es) Conjugados de neurturina novedosos para uso farmaceutico.
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
WO2013114400A3 (en) Compressed pharmaceutical compositions of atypical antipsychotics
WO2009140105A3 (en) Formulations for cathepsin k inhibitors
WO2013074871A3 (en) Humanin analogs
IL206739A (en) An injectable drug containing silitol as an active substance